|
|
|
|
|
|
By Mathini Ilancheran, Beroe Inc. | Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them. | |
|
|
| Driving Operational Excellence Using Machine Learning | White Paper | By Tobias Kutscher and Dr. Alexander Krauland, Boehringer Ingelheim Biopharmaceuticals GmbH | Explore how advanced machine learning and data analytics are revolutionizing biopharmaceutical manufacturing and driving operational excellence. |
|
|
| Linker Design Approaches To Improve ADC Stability And Activity | Poster | By Kern H. Chang, Hana Yu, Myunghoe Heo, et al., LOTTE Biologics | ADC design choices shape efficacy and selectivity. Hydrophilic modifications are evaluated for their effects on cytotoxic activity, target specificity, and cell viability across multiple tumor models. |
|
|
|
|
| Benefits Of Isolator Technology In Fill-Finish | Article | By Sabrina Zirkle, Jubilant HollisterStier | Isolator technology enhances sterility assurance, reduces contamination risk, improves operator safety, and supports regulatory compliance, making it essential for modern aseptic fill-finish operations. |
|
|
|
|
| Digging Into Manufacturing Priorities For Viral Vectors | Article | Novartis Contract Manufacturing | Addressing the complexities of viral vector manufacturing through strategic internalization, advanced technologies, and regulatory excellence is crucial for the future of gene therapies. |
|
|
| Why Cell And Gene CDMOs Benefit From Digitalization | Article | Koerber Pharma | Get to know why digitization is crucial for cell and gene contract manufacturers by learning the various benefits digital transformation can offer such as efficiency, compliance, and innovation. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Webinar: Strategic Early Material Generation for Accelerated Process Development | Accelerating access to early-stage material is critical for efficient biologics development. In this webinar, Samsung Biologics shares its integrated approach to early material generation, aligning with cell line development to deliver scalable, production-relevant material faster. Learn how this strategy supports developability assessment, reduces variability, and enables efficient downstream activities, with case studies demonstrating improved timelines, resource use, and overall program success. Click here to learn more. |
|
|
| Connect With Bioprocess Online: |
|
|
|
